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Although many studies have shown the great potential of induced hypothermia in stroke treatment, we recognize that there are
limitations to the protective eﬀects of hypothermia even in the laboratory. Here, we review our experiments on the protective
eﬀects of mild-to-moderate hypothermia in rats. Focal ischemia was induced by bilateral common carotid artery (CCA) occlusion
for 1 to 2 hours combined with permanent or transient middle cerebral artery (MCA) occlusion. We compared the eﬀects of
mild (33
◦C) and moderate (30
◦C) hypothermia, evaluated therapeutic time windows, and studied the underlying mechanisms.
On review, our ﬁndings revealed that the protective eﬀects of induced mild hypothermia (33
◦C) were limited, and the therapeutic
time window of even moderate hypothermia (30
◦C) was very short in our speciﬁc models, although this limitation might be due
to the relatively brief periods of hypothermia used. In addition, we found that hypothermia reduced brain injury by preserving
Akt activity, PTEN phosphorylation and εPKC activity, while inhibiting ROS production, and δPKC activity.
1.Introduction
One of the gold standards of neuroprotectants against
stroke in animal experiments [1, 2] induced mild (33 to
36◦C) to moderate (28 to 32◦C) hypothermia has been the
focus of several clinical trials for the treatment of cerebral
ischemia. In the past decade, prospective randomized con-
trolled studies have demonstrated that induced hypothermia
improves neurological function in patients suﬀering cardiac
arrest from ventricular ﬁbrillation [3] and reduces risk of
death or disability in neonates following hypoxic-ischemic
encephalopathy [4, 5]. However, the clinical translation of
hypothermia for acute stroke treatment is still in its early
stages.Manybarriersremain,includingonsettime,duration,
and depth of hypothermia [6].
In the process of extrapolating animal studies to human
patients, signiﬁcant gaps exist even between the design
of laboratory experiments and clinical trials. For instance,
many previous animal models used complete reperfusion
[7–9], while most stroke patients suﬀer from permanent
cerebral artery occlusion [10, 11]. Even with t-PA treatment,
slightly less than one third of patients achieve complete
reperfusion, one-third achieve partial reperfusion, and in
the rest reperfusion is absent [11, 12]. Therefore, the ability
to select animal stroke models that properly mimic clinical
stroke is a critical step in evaluating the protective eﬀects of
induced hypothermia.
Our laboratories have studied the protective eﬀects of
mild-to-moderate hypothermia for nearly two decades [6,
13–17]. Our recent hypothermia studies use a focal ischemic
model with partial reperfusion in rats [16, 18, 19]; a model
which is less frequently used in other laboratories. In this
model, stroke is induced by bilateral common carotid artery
(CCA) occlusion combined with permanent distal middle
cerebral artery (MCA) occlusion [16, 20–22]. The bilateral
CCAs are reopened 1 to 2 hours later while the distal MCA
remains occluded [16, 19, 23, 24]. This technique therefore
allows partial reperfusion [25, 26]. As discussed above, this
model mimics many stroke patients who receive partial
reperfusion, with or without t-PA treatment. However, to
compare the protective eﬀects of hypothermia in focal
ischemia with partial reperfusion and complete reperfusion,2 Stroke Research and Treatment
we also used a model with transient three-vessel (bilateral
CCAs and distal MCA) occlusion [18].
Several excellent articles have reviewed the protective
eﬀects of hypothermia as function of onset time, duration,
anddepthofhypothermia,aswellasitsunderlyingprotective
mechanisms [27–30]. Particularly, van der Worp et al.
have comprehensively reviewed past hypothermic studies
[29], which either used temporary or permanent occlusion
models. However, the protective aﬀects of hypothermia in
stroke models using partial reperfusion as described above
have received signiﬁcantly less attention. Therefore, this
paper focuses mainly on our studies of the past several
years on therapeutic time windows and the unique model of
partial reperfusion.
2. IntraischemicModerate Hypothermia
Offers Strong and Long-Term Protection
inaFocalIschemicModel
with Partial Reperfusion
In our ﬁrst implementation of an ischemic model [16], we
cauterized the distal MCA above the rhinal ﬁssure and tran-
siently occluded the bilateral CCAs for 1 hour. This model
generates a well-delineated ischemic area limited to the
cortex [20, 22]. Moderate hypothermia (30◦C) monitored at
the core body temperature was induced 10 minutes before
ischemia onset and maintained for 1 hour after ischemia
onset [16]. Although we did not directly monitor brain tem-
perature, we previously observed a high correlation between
rectal temperature and brain temperature in hypothermic
rats [21]. We should add that because brain temperature in
normothermic rats drops spontaneously during occlusion,
core temperature may not accurately reﬂect brain tempera-
ture [2, 31]. Even so, we did not experimentally adjust any
potential changes in brain temperature in order to minimize
the introduction of possible artiﬁcial factors, which would
likely exacerbate ischemic injury once the brain was heated.
Our results showed that hypothermia reduced infarct size
more than 80% compared with normothermia at 2 days after
stroke (Figure 1(a))[ 16]. Because some neuroprotectants
oﬀer transient protection, we also measured brain injury
2 months later and found similar protective eﬀects at 60
days and 2 days (Figure 1(b)), suggesting that hypothermia
decreases ischemic damage over the long term rather than
merely delaying its emergence. This protective eﬀect is
furtherstrengthenedbytheeﬀectsofhypothermiaonbehav-
ioral deﬁcits after stroke, which showed that hypothermia
improved neurological functioning for up to 2 months [16].
We then used this model to study the underlying
protective mechanisms related to the PI3K/Akt cell signaling
pathway [16]. The PI3K/Akt kinase pathway is known to
promote neuron survival postischemia (reviewed by [32])
Figure 2. Akt activity is regulated by phosphorylation at Ser-
473 and Thr-308 via upstream molecules, such as PDK1 and
PTEN. While activated PDK1 phosphorylates Akt, activated
PTEN dephosphorylates Akt. Activated Akt then blocks cas-
pase/cytochrome c-mediated apoptosis by phosphorylating
Akt substrates, such as FKHR and GSK3β. In our study,
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Figure 1: (Revised from [16]). Intraischemic moderate hypother-
mia (30◦C) reduces infarct size in a focal ischemia with partial
reperfusion. Focal ischemia was induced by 1h of bilateral CCA
occlusion and permanent dMCAo. Body core temperature was
loweredto30◦C10minbeforestrokeonsetbyspraying70%alcohol
on the rat body. (a) The upper panel shows representative infarcts
stained with cresyl violet from rats euthanized 2d after stroke. The
paleareawithasterisksrepresentstheinfarctregion.Normothermic
ischemia damaged the cortex ipsilateral to the occluded MCA,
whereas hypothermia spared all or most of the injured cortex.
Only a small lesion was observed in the presented section from
a hypothermic rat. The bar graphs represent statistical analysis
of infarct size 2d after stroke. Two-way ANOVA (two factors,
temperature and brain section level) was used to compare the eﬀect
of temperature on the infarct size at each level (data not shown)
and on the mean of all 4 levels. Hypothermia (n = 7) reduced the
mean infarct size by 80% compared with normothermia (n = 7;
P = 0.001). (b) The upper panel shows representative sections
stained with cresyl violet from animals surviving 2 months after
stroke. Most of the cortex in the infracted hemisphere was lost in
normothermic but not hypothermic rats. The lower panel of bar
graphs shows infarct size 60 d after stroke. Hypothermia (n = 9)
reduced infarct size 60d after stroke compared with normothermia
(n = 8; P = 0.001). # versus 37◦C, P<0.001.Stroke Research and Treatment 3
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Figure 2: Diagram showing the major cascades that occur after
stroke reviewed in this paper. AD: anoxic depolarization; AIF:
apoptosis-inducing factor; BBB: blood brain barrier; CBF: cerebral
bloodﬂow;cytoc:cytochromec;FasL:Fasligand;FKHR:Forkhead
homologue in rhabdomyosarcoma; Glu: glutamate; GSK 3 β:
glycogen synthase kinase 3β; MMP: matrix metalloprotease; NOS:
nitric oxide synthesis; NO: nitric oxide; ONOO−: peroxynitrite;
PI3K: phosphoinositide 3-kinase; PIP2: phosphatidyliositol-4,5-
bisphosphate; PIP3: phosphatidyliositol-3,4,5-bisphosphate; PKC:
protein kinase C; P-Akt: phosphorylated Akt; PTEN: phosphatase
and tensin homologue deleted on chromosome 10; P-PDK1: phos-
phorylated phosphoinositide-dependent protein kinase-1; ROS:
reactive oxygen species; RTK: receptor tyrosine kinase; VDCC:
voltage-dependent calcium channel.
stroke resulted in transient increases in phosphorylated Akt
(P-Akt) levels, but led to a reduction in phosphorylation
levels of PTEN, PDK1, GSK3β, and FKHR [16]. However,
in vitro Akt kinase assays showed that true Akt activity was
decreased after stroke. Although hypothermia blocked the
increase in P-Akt after stroke, it maintained true Akt activity.
A functional role for this hypothermia-maintained activity
is supported by the ﬁnding that the PI3K/Akt inhibitor,
LY294004, enlarged infarct size in hypothermic animals. In
addition, hypothermia attenuates a decrease in P-PTEN after
stroke onset. Taken together, our results suggest that the
PI3/Akt pathways play a critical role in the neuroprotection
observed in intraischemic moderate hypothermia [16].
We also studied the potential roles of two critical
components in the protein kinase C (PKC) pathway: δPKC
[24]a n dεPKC [23]. δPKC is a kinase strongly implicated in
executing ischemic damage while εPKC is neuroprotective
[33]. We found that intraischemic hypothermia (30◦C)
blocks translocation of δPKC to the mitochondria and
nucleus and attenuates δPKC cleavage [24], but it promotes
εPKC activity, as evidenced by increased εPKC phosphory-
lation levels [23]. Therefore, our results suggest that both
δPKC and εPKC may participate in the protective eﬀects of
intraischemic moderate hypothermia.
3. IntraischemicMild Hypothermia(33◦C)
Fails to Offer Protection in a More Severe
Ischemic Model with PartialReperfusion
In our second study we compared the protective eﬀects of
mild (33◦C) and moderate hypothermia (30◦C) [19] either
transiently induced during or after CCA occlusion or main-
tained during and after CCA occlusion. For stroke models,
we extended the bilateral CCA occlusion period from 1 to 2
hours, while the distal MCA remained occluded (Figure 3)
[19]. The hypothermic duration at both temperatures was
either 2 hours during or after CCA occlusion or 4 hours
during and after CCA occlusion. We found that 2 hours
of mild hypothermia (33◦C) induced either during or after
CCA occlusion did not confer protection [19]. This was
unexpected because our previous study showed that 2 hours
of intraischemic hypothermia (33◦C) reduced infarct size
in a 2-hour MCA suture occlusion model in rats [14]. In
addition, as van der Worp et al. [29] reviewed, previous
studies have reported a substantial reduction in infarction
even at 35◦C, when hypothermia commenced before or at
the start of MCA occlusion, with protective eﬀects that were
not clearly time dependent.
In our study, however, 4 hours of mild hypothermia
applied during and after CCA release slightly, but signiﬁ-
cantly,reducedinfarctsizeby22%.Whenwefurtherreduced
hypothermia from 33◦Ct o3 0 ◦C, 2 hours of moderate
hypothermia during CCA occlusion increased protection,
signiﬁcantly reducing infarct size by 46% (Figure 3). Nev-
ertheless, 2 additional hours of moderate hypothermia (4
hours total) did not oﬀer additional protection, suggesting
a limited eﬀect of prolonged moderate hypothermia applied
during and after CCA release [19].
Using confocal microscopy and Western blotting, we
found that when intraischemic hypothermia reduced infarct
size, the subcellular translocation of cytochrome c and
apoptosis-inducing factor (AIF) was blocked in the ischemic
penumbra. However, when hypothermia (either intrais-
chemic or delayed mild hypothermia) did not reduce infarct
size, no eﬀect was observed on these proapoptotic factors
[19]. This suggests that inhibition of cytochrome c and AIF
release corresponded to the protective eﬀect of hypothermia.
4. LimitedTherapeutic Time Windows of
Moderate Hypothermia (30◦C)inaFocal
Ischemia withComplete Reperfusion
After comparing the protective eﬀects of both mild and
moderate hypothermia in severe ischemic models with4 Stroke Research and Treatment
1
2
3
4
5
6
37 37
37
37
37
33 33
33
33
30 30
30
(a)
(b) (c)
80
60
40
20
0
123456
Experimental groups
33◦C/33◦CC 30◦C/30◦
37/37 33/37 37/33 33/33 30/37 30/30
2h CCAo 2h CCAr 48h
37◦C/37◦C
(◦C)
I
n
f
a
r
c
t
s
i
z
e
(
h
e
m
i
s
p
h
e
r
e
(
%
)
)
∗∗
∗
# versus groups 1,2,3 (P<0.001)
##
#
## #
##
v e r s u sg r o u p4( P<0.05)
∗ versus group 3,6 (P<0.05)
∗∗ versus groups 1,2,5 (P<0.01)
Figure 3: (Revised from [19]) (a) Protocols for surgery and temperature management. Six groups of rats were studied. The distal MCA was
occluded permanently. The black portion of the bar represents bilateral CCA occlusion (CCAo) for 2h, and the gray portion indicates 2h
of temperature management after CCA release (CCAr), including 30◦C, 33◦C, and 37◦C. Rats were allowed to survive for 48h after stroke.
(b) Photographs of representative infarct sections after cerebral ischemia from groups 1, 4, and 6. Permanent distal MCA occlusion plus 2h
of bilateral CCA occlusion caused an infarct in the ipsilateral cortex of the occluded MCA (left, group 1). A coronal section from Level 2
is presented. Four hours of mild hypothermia (center, group 4) mildly decreased infarct size. When the temperature was reduced to 30◦C
robust protection was observed (right, group 6). (c) Bar graph showing that hypothermia reduces infarct size after stroke only under certain
conditions. A mean infarct size for each group was calculated as the sum of all 4 levels for each animal divided by the number of animals
in each group. The infarct size did not diﬀer among groups 1 through 3. However, the infarct in group 4 was reduced about 22% relative to
group 1. When the temperature was decreased to 30◦C (group 5) robust protection was observed; an additional 2h of hypothermia in group
6 did not further reduce infarct size.
permanent distal MCA occlusion, we were not optimistic
that mild hypothermia (33◦C) could achieve protection.
Thus, we focused on the therapeutic time window for
moderate hypothermia (30◦C) in a transient focal ischemic
model with 1 hour of CCA and distal MCA occlusion, which
allows complete reperfusion (Figure 4)[ 18]. Our aim was
to determine the potential therapeutic time window for a
brief moderate hypothermia in a less severe ischemic model.
We found that 3 hours of moderate hypothermia started
immediately after stroke onset spared almost all infarction
(Figure 4(b)), and 3-hours of early moderate hypothermia
induced 45 minutes after CCA occlusion markedly reduced
infarction by more than 80%, whereas delayed hypothermia
initiated 15 minutes after reperfusion did not prevent
ischemic damage (Figure 4(b))[ 18]. Together, these results
suggest a very short therapeutic time window for a brief,
moderate hypothermia.
Our study on therapeutic time windows is limited by
the short 3-hour duration of hypothermia. It is highly likely
that the delayed onset of hypothermia would have been
protective if prolonged hypothermia had been used. For
instance,Colbourneetal.foundthatprolongedhypothermia
(24 hours of 33◦C plus 24 hours of 35◦C) started 2.5 hours
after the onset of ischemia robustly reduced infarct volume
and attenuated behavior deﬁcits in a focal ischemia model
with a 90-minute MCA occlusion in rats [34]. Clark et al.
reported that hypothermia (33◦C) lasting 12, 24, or 48
hours was required to reduce infarct size and improve
functional outcomes when hypothermia was instituted 1
hour after permanent distal MCA and CCA occlusion, and
prolonged hypothermia (24 or 48 hours) was better than
shorter hypothermia (12 hours) [35]. Furthermore, delayed
hypothermia beginning 1 hour after ischemia appears to
require prolonged periods (12 to 24 hours) to generate
protection even for global ischemia lasting just 5 minutes
[36]. Therefore, the limited therapeutic eﬀects of post-
ischemic hypothermia in our studies may be speciﬁc to the
experimental settings in our laboratory.
Consistent with its protective eﬀects, early hypothermia,
but not delayed hypothermia, blocked TUNEL positive
staining, a marker for apoptosis or cell death [18]. In
addition, we found that early hypothermia attenuated the
generation of superoxide compared with normothermia.
However, both early and delayed hypothermia attenuated
reductions in Mn-SOD protein levels and δPKC cleavage in
the ischemic penumbra, suggesting that both Mn-SOD and
δPKC cleavage may not be responsible for the diﬀerential
protective eﬀects of early and delayed hypothermia [18].
In addition, both early and delayed hypothermia preserved
Akt phosphorylation. Nevertheless, only early hypothermia,
but not delayed hypothermia, maintained PTEN phospho-
rylation (P-PTEN) [18], suggesting that P-PTEN may playStroke Research and Treatment 5
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Figure 4: (revised from [18]) Limited therapeutic time windows
for post-ischemic moderate hypothermia in a focal ischemia with
complete reperfusion. (a) A diagram for experimental procedures
comparing the protection of hypothermia. Rats were divided into 4
groups.Group1,normothermia:bodytemperaturewasmaintained
at 37◦C throughout the experiment. Group 2, intraischemic
hypothermia: hypothermia was induced at ischemic onset and
maintained for 3h. Group 3, early hypothermia: body temperature
was adjusted to 30◦C 15min before reperfusion and maintained for
3h. Group 4, delayed hypothermia: body temperature was adjusted
to 30◦C 15min after reperfusion and maintained for 3h. (b) The
upper panel shows representative infarcts stained by TTC. White
areas are the infarct regions. The lower panel shows quantitation of
infarct volumes. Values are mean ± S.E.M. (n = 8 per each group).
∗∗∗P < 0.0001, versus normothermia.
a critical role in the protective eﬀects of early hypothermia
through the attenuation of ROS activity.
5. Discussion
As we have discussed, hypothermic studies performed in
the laboratory have led to clinical investigations for cerebral
ischemia. Signiﬁcant enthusiasm for this approach still exists
in the scientiﬁc community. A number of preliminary
clinical trials (mostly phase I) to conﬁrm the feasibility
and safety of induced mild hypothermia for stroke patients
have been completed, and several phase II clinical trials
arecurrentlyinprogress(http://clinicaltrials.gov/).However,
whether mild-to-moderate hypothermia can be successfully
translated clinically or, if successful, how long this will take
has yet to be determined.
The purpose of our basic research using animal models
is to provide the rationale for clinical translation, although
we cannot directly extrapolate settings from the laboratory
to clinical trials. As discussed, our laboratory experiment is
limited due to the short 3-hour duration of hypothermia,
which contrasts to human clinical trials where hypothermia
may last a few days. In addition, our study used infarct
size as the criteria for evaluating the protective eﬀects of
hypothermia and not neurological function, as is often the
case in clinical studies. Despite these limitations, our results
serve as a warning of the persistent challenges we must
confront as we seek to translate hypothermia to the clinic.
First of all, the most strikingly disappointing results from
our studies are the limited protective eﬀects of hypothermia,
including mild hypothermia, and the short therapeutic time
window of moderate hypothermia. If these observations are
true, successful clinical translation of induced hypothermia
may prove to be more diﬃcult than anticipated to achieve.
For example, we demonstrated that even intraischemic
mild hypothermia (33◦C) induced before ischemic onset
failed to reduce infarct size in a focal ischemia model with
permanent distal MCA occlusion and partial reperfusion
upon bilateral CCA release. This model may be more severe
than the model of MCA suture occlusion with reperfusion
used by most laboratories, but we have no reason to believe
it is more severe than strokes in humans. As previously
discussed, many stroke patients suﬀer from permanent
cerebral artery occlusion without reperfusion. To achieve
protection, even our experimental ischemic models required
reducing intraischemic hypothermia to 30◦C or prolong-
ing intraischemic mild hypothermia beyond CCA release.
However, applying intraischemic hypothermia before stroke
onset in clinical trials is nearly impossible, and inducing
hypothermia in stroke patients beyond 33◦Ct o3 0 ◦Ci sv e r y
diﬃcult. Clinical trials often use mild rather than moderate
hypothermia, and it takes signiﬁcantly longer to reach the
target temperature compared to experimental stroke in
animal models.
Nevertheless,aswereviewedpreviously[6],othergroups
have shown that intraischemic mild hypothermia elicits
protection even in permanent MCA occlusion models, in
contrast to our recent studies. Our negative ﬁndings may
simply reﬂect our speciﬁc setting and use of a unique model.
Second, the therapeutic time window for moderate
hypothermia is extremely narrow after stroke onset, even
in the 1-hour transient focal ischemic model. To achieve
protection, 3 hours of moderate hypothermia must be
inducedasearlyas45minutesafterstrokeonset;a30-minute
delay rendered the moderate hypothermia ineﬀective. Again,
it is highly unlikely that most stroke patients can receive
hypothermic treatment within 1 hour of stroke onset. In
most clinical studies, mild-to-moderate hypothermia was
initiated as late as 5 to 6 hours after stroke, and one to several
hours were required to reach target temperatures [37, 38].
In addition, patients may not have reperfusion, or if there is
reperfusion, it may occur at a very late stage.
Our studies on the underlying protective mechanisms
may also oﬀer some alternative clues or applications for clin-
ical trials. For instance, we demonstrated that hypothermia6 Stroke Research and Treatment
reduces infarct size by preserving Akt activity and PTEN
phosphorylation and by inhibiting ROS activity. If possible,
pharmacological agents may be developed that improve Akt
activity while inhibiting PTEN activity, or attenuating ROS
production, and such pharmacological agents may be used
in combination with induced hypothermia.
In summary, despite confounding issues, laboratory
studieshaveprovidedstrongrationaleforclinicalapplication
of hypothermia for acute stroke treatment. In clinical
settings, a number of crucial variables need to be consid-
ered, including the onset time of hypothermia, its depth,
and whether the strokes studied include reperfusion. Early
reperfusion and rapid hypothermia initiation should be used
to achieve maximal protection.
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